THCV, or tetrahydrocannabivarin may have the potential to help with energy, focus/attention, and eve appetite, weight/BMI. In fact, in a study of 900 adults aged 21 and older in the U.S.,
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid program. Tetrahydrocannabivarin, also known as THCV, or d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better-known major cannabinoid, tetrahydrocannabinol. While these two cannabinoids share a similar structure and name, they have very different physiological effects. Notably, unlike THC which is intoxicating and produces a “high” or euphoric effect, and is a scheduled compound that is federally illegal unless prescribed by a physician, THCV is non-intoxicating and is not a scheduled compound. Success could also be positive for companies such as Tilray Inc. (NASDAQ: TLRY), Canopy Growth (TSX:WEED) (NASDAQ: CGC), Jazz Pharmaceuticals (NASDAQ: JAZZ), and AbbVie Inc. (NYSE: ABBV).
InMed Pharmaceuticals Inc. (NASDAQ: INM) to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV
InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin on energy, focus/attention, appetite and weight/BMI. BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie.
This rare cannabinoid, consumer-based investigation will measure the effects of the Company’s d-9 dominant THCV in a randomized, blinded, placebo-controlled study in up to 900 adult participants aged 21 and older who reside in the United States. The study includes three dosing groups including a placebo group (no THCV), each delivered via Trokie’s proprietary lozenge technology. The study is set to begin participant recruitment in May and will run for a four week period starting in June with results expected during the summer. The study is part of Radicle Science’s large scale investigations into several rare cannabinoids involving up to 10,000 participants in total, the largest of its kind to date.
“We are excited to be part of this groundbreaking study with Trokie and Radicle Science in advance of our commercial launch of d-9 dominant THCV. Radicle Science has been at the forefront of cannabinoid research, providing much needed scientific evidence to validate the effects of cannabinoids, and Trokie is a leader in unique and effective delivery systems for cannabinoids,” said Dr. Shane Johnson, SVP and General Manager of BayMedica. “As a company driven by data and science, independent third-party research provides important information as we continue to expand our product portfolio of rare cannabinoids for the health and wellness market. Evidence-based decision making is key to facilitate adoption of rare cannabinoids by consumers, brands and healthcare providers. This research will advance the understanding of rare cannabinoids, which have been historically under-investigated.”
Dr. Emily Pauli, Pharm.D, Chief Research Officer of Radicle Science, added, “Consumers have been reporting anecdotal benefits from THCV; but, to date, we have sparse evidence on it and other rare cannabinoids. We look forward to analyzing the results of this inaugural study of THCV, which is the first of its kind in a consumer-driven setting. With the large number of participants, we can assess whether there are meaningful improvements with energy and focus, as well as any impact on appetite. With our innovative AI-enabled approach, we can study diverse Americans across the country - which may also reveal personalized factors that impact the effect of THCV.”
“This study continues Trokie’s commitment to developing products based on scientific evidence and rigorous standards” said Gavin Chandler, CFA, CEO and President of Trokie. “The Radicle Science Discovery platform is the gold standard in the health and wellness industry for understanding how cannabinoid products can provide health benefits across many different populations. We are excited to partner with BayMedica on this study, with their differentiated rare cannabinoids of exceptional quality and purity, which matches our product philosophy.” Trokie’s Advisory Board member, Jordan Tishler, MD, President of the Association of Cannabinoid Specialists and faculty at Harvard Medical School, added, “The Radicle Energy study will significantly add to the body of knowledge regarding the health effects of lesser known cannabinoids like THCV. The combination of Trokie’s novel delivery system, BayMedica’s high purity cannabinoids, and Radicle’s Discovery study platform provide an excellent opportunity to learn more about how these products can improve human health.”
BayMedica – We do cannabinoids differently
BayMedica manufactures rare cannabinoids through novel synthetic methods that ensure reproducible quality and purity. The Company’s products are manufactured under food-grade GMP (Good Manufacturing Practice) standards for the health and wellness sector, and are bioidentical to plant-derived compounds. These cannabinoids can be custom formulated for a variety of consumer health and wellness applications including supplements, nutraceuticals, cosmetics and animal health. Utilizing reproducible processes guarantee the purity and consistency of our cannabinoids each and every time. Furthermore, these production methods can be scaled up to meet demand to ensure that clients have an ongoing source of cannabinoids without supply chain concerns. BayMedica has large scale batches of cannabidivarin, cannabichromene and cannabicitran available for wholesale purchase and will be commencing B2B sales of d-9 dominant tetrahydrocannabivarin soon.
About THCV:
Tetrahydrocannabivarin, also known as THCV, or d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better known major cannabinoid, tetrahydrocannabinol (“THC”). While these two cannabinoids share a similar structure and name, they have very different physiological effects. Notably, unlike THC which is intoxicating and produces a “high” or euphoric effect, and is a scheduled compound that is federally illegal unless prescribed by a physician, THCV is non-intoxicating and is not a scheduled compound.
Learn more about InMed’s Cannabinoids in Development: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/
Learn more about BayMedica’s THCV:
https://www.baymedica.com/tetrahydrocannabivarin-thcv/
Learn more about BayMedica’s CBC:
https://www.baymedica.com/cannabichromene-cbc/
Other related developments from around the markets include:
Tilray Inc. reported financial results for the third fiscal quarterended February 28, 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, stated, “Our third quarter results reflect progress and momentum across all of our key business segments and geographies, setting the stage to achieve our target for $4B in revenue by the end of fiscal 2024. Tilray Medical – which now operates under a cohesive strategy and mission – has a near 20% share in Germany, providing clear benefits in its own right as well as a first-mover advantage that we will leverage as Germany and the EU move towards broader adult-use and medical use legalization. In Canada, we maintained our leading market share position amid intense competition – and believe that our strong capital position, operational excellence and pricing and marketing adjustments will work in concert to help ensure we reclaim share in the coming quarters. This effort will gain further support from the fundamental appeal of our brands and product innovation which, as stores continue re-opening, will resonate powerfully with consumers. In the U.S., our SweetWater Brewing, Breckenridge Distillery, and Manitoba Harvest businesses are profitable, growing and emerging as nationwide, iconic brands with loyal followings that will be home to THC-based products upon U.S. federal legalization.”
Canopy Growth announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to accelerate its path to profitability. “To realize profitability and power growth, we are taking critical actions to further evolve Canopy Growth into an agile organization with a clear focus on the areas where we have the greatest potential of success,” said David Klein, Canopy Growth Chief Executive Officer. “These necessary changes are being implemented to ensure the size and scale of our operations reflect current market realities and will support the long-term sustainability of our company.”
Jazz Pharmaceuticals announced financial results for the first quarter of 2022, raised 2022 financial guidance and provided business updates. "We're pleased to raise our top- and bottom-line guidance, driven by our continued execution and significant progress across commercial and R&D in the first quarter, which positions us well for the rest of the year and to achieve Vision 2025," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals. "Our recent launches of Xywav®, in both narcolepsy and idiopathic hypersomnia (IH), and Rylaze® in acute lymphoblastic leukemia (ALL), continue to generate increased prescriber and patient adoption, and demonstrate our ability to deliver innovative new medicines to improve the lives of patients and their families. On the corporate development front, our three recent transactions are aligned with our broader strategy, allowing us to focus on our highest priorities, enhance our pipeline in areas of key interest in neuroscience and oncology and drive long-term shareholder value."
AbbVie Inc. announced financial results for the first quarterended March 31, 2022. "This year is off to a strong start. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year."
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. InMed Pharmaceuticals Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of InMed Pharmaceuticals Inc. Click here for disclaimer.
Contact Information:
2818047972
[email protected]
